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Assembly PCR synthesis of 
optimally designed, compact, 
multi-responsive promoters suited 
to gene therapy application
H. Mohamed, Y. Chernajovsky & D. Gould
Gene therapy has the potential to provide innovative treatments for genetic and non-genetic diseases, 
with the ability to auto-regulate expression levels of therapeutic molecules so that they are produced 
locally and in direct response to disease activity. Generating disease responsive gene therapy vectors 
requires knowledge of the activation profile of transcription factors (TFs) during active disease, in order 
to assemble binding sites for these TFs into synthetic promoters, which can be appropriately activated 
by the disease process. In this study, we optimised a PCR random assembly approach to generate 
promoters with optimal spacing between TF binding sites (TFBSs) and their distance from the TATA box. 
In promoters with optimal spacing, it was possible to demonstrate activation by individual transcription 
pathways and either additive or synergistic promoter activation when transfected cells were treated 
with combined stimuli. The kinetics and sensitivity of promoter activation was further explored in 
transduced cells and when lentivirus was directly delivered to mouse paws a synthetic promoter 
demonstrated excellent activation by real-time imaging in response to local inflammation.
After 30 years of endeavour, there are a growing number of gene therapy successes in both monogenetic1–6 and 
polygenetic conditions7–10. With each success, the potential for gene therapy expands and the array of gene 
therapy tools increases. To date these strategies have involved either ex vivo engineering of stem cells which 
are re-introduced to patients or in vivo direct delivery of vectors to patients. There is however, further scope to 
increase the specificity of gene therapy approaches to achieve more advanced and innovative treatments. One 
approach is the development of ‘physiologically responsive’ gene therapy. This term was coined by Varley and 
Munford in 199811 to describe the use of endogenous promoters that drive expression of therapeutic proteins 
in direct response to disease stimuli. The authors demonstrated the inflammation responsiveness of promoters 
for the acute phase proteins; complement factor 3 (C3) and serum amyloid A3 (SAA3), following delivery to the 
mouse liver with adenoviral vectors12.
Several responsive endogenous promoters have been utilised in experimental gene therapy studies13–15, as well as 
hybrid promoters such as IL-1E/IL-6P which is composed of an enhancer from the IL-1 promoter (− 3690/− 2720) 
and the proximal IL-6 promoter (− 163/+ 12)16–18. However, the size of endogenous and hybrid promoters is usu-
ally in excess of 1 Kb which can preclude their application in vectors where there is limited capacity. Endogenous 
promoters can also harbour binding sites for TFs not relevant to the disease process which could lead to inappro-
priate promoter induction and unwarranted activation profiles that do not mirror the course of the disease for 
which they are intended.
An alternative approach is to generate smaller synthetic promoters in which cis-acting recognition motifs 
for a particular TF are cloned upstream from a core promoter. Promoters of this type, such as NF-κ B and 
HIF-1α responsive promoters have been explored in experimental gene therapy applications19–26, however, 
mono-responsive synthetic promoters are unlikely to have an activation profile that mirrors the course of a dis-
ease in its entirety, therefore, it would be logical to utilise promoters that are activated by several TFs relevant to 
the disease process under study. In a previous study different TFBSs were combined to create a multi-responsive 
synthetic promoter, but additive induction was not observed with combined stimulation27.
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In this study, we aimed to generate compact and optimally functioning multi-responsive promoters with low 
basal activity in the absence of stimulation and dose dependent additive induction with increasing stimulation. 
We utilised a PCR assembly method to generate promoters and explored the optimal spatial arrangement of 
TFBSs relative to each other and to the TATA box within the core promoter. We then applied this optimal tem-
plate to the generation of promoters harbouring TFBSs for three different TFs and demonstrate that with ran-
domly assembled promoters we can yield synthetic promoters with the induction characteristics we required. 
Induction of these promoters was fully characterised in vitro and when tested in vivo they displayed appropriate 
activation in a disease model.
Results
Activity of mono-responsive promoters in cells exposed to multiple stimulation. Disease 
pathology is complex with the activation and involvement of multiple cell signalling pathways at different stages 
of disease progression. As such, profiling of disease responsive promoters applicable to gene therapy application 
should not be limited to activation of their responsive pathway but should also be monitored when other disease 
related pathways are activated. We therefore examined the activation of previously reported mono-responsive 
promoters in transfected cells. These studies showed that a hypoxic responsive promoter in the plasmid pH-Luc23 
was activated by hypoxia (0.1%) with a 43 fold increase in luciferase activity but when transfected cells were stim-
ulated with hypoxia, TNFα and PMA in combination, the induction was significantly lower at 27 fold. Similarly, 
the NF-κ B promoter in pGNL620 was induced with TNFα by 107 fold, but the same combined stimulation only 
resulted in an induction of 34 fold (Fig. 1). These findings illustrate that either mono-responsive promoters need 
to be designed carefully so that they retain full activity even when other transcriptional pathways are activated 
or alternatively, multi-responsiveness should be built into promoters so that other relevant transcription factors 
contribute to their activation.
Influence of close TFBS alignment in composite promoters on basal promoter activity and 
induction. Many previously reported synthetic regulated promoters have been assembled with TFBS closely 
aligned to each other21,28 so we explored this approach to generate multi-responsive synthetic promoters. Initial 
experiments were performed by combining binding sites for the TFs NF-κ B, AP-1 and HIF-1α (with a 4 bp 
separation between each TFBS) upstream of the mCMV promoter and the firefly luciferase reporter gene, by 
random ligation of pre-annealed oligonucleotides (sequences detailed in Supplementary Table 1). The sequences 
of these promoters (n = 13) were determined (Supplementary Material Appendix) and are represented schemati-
cally (Fig. 2A). In transiently transfected 293T cells, the majority of the promoters exhibited high basal luciferase 
expression (average of 186.7 RLU) in comparison to the basal activity demonstrated by the mCMV core promoter 
within the negative control plasmid (5.4 RLU) (Fig. 2B). Promoters with few TFBS inserts displayed lower basal 
activity and generally, increasing the TFBS number resulted in higher basal activity. In terms of induction, the 
4bp-composite promoters were generally responsive to each individual stimuli in accordance with their TFBS 
composition (Fig. 2C), however, due to their elevated basal activity, low fold inductions were generally observed 
(Fig. 2D). Promoter 15 displayed a combined induction in excess of 15 fold and this promoter consisted of a 
single TFBS for each transcription factor resulting in low basal activity. Despite being responsive to each stimuli, 
promoter 15 did not display additive induction following combined stimulation. The general lack of additive 
induction in these promoters may have been due to the close proximity of TFBSs which could have resulted in 
the steric hindrance of adjacent TF binding. We therefore explored whether the spatial arrangements of TFBSs 
could be optimised to reduce basal promoter activity and facilitate additive induction of composite promoters.
Optimised construction of synthetic promoters by Assembly PCR. The Assembly PCR method is 
a two-step PCR approach (assembly and amplification) conventionally used to synthesise genes from multiple 
Figure 1. Compromised function of mono-responsive promoters upon multiple stimulation. 293T cells 
were transfected with constructs and were either unstimulated (white bars) or stimulated with hypoxia (0.1% 
O2 – HIF-1α ) (blue bars), TNFα (10 ng/ml – NF-κ B) (green bars), PMA (10 ng/ml – AP-1) (red bars) or 
their combination (grey bars)(the same colour for stimulation is used in subsequent figures). After 24 hours 
luciferase activity in cell lysates was quantified and mean values of triplicate normalised readings plotted with 
vertical lines representing the SEM. The responsiveness of each promoter to stimulation was also analysed by 
1 way ANOVA (within each promoter) which showed significant differences. A post-hoc Šidak test was then 
performed to determine when the activity with combined stimulation (grey bars) was significantly (p < 0.05) 
lower than the highest activation caused by an individual stimuli this is indicated by ★.
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overlapping oligonucleotides29. Modifications to the Assembly PCR method described by Team Heidelberg 
(http://2009.igem.org/Team:Heidelberg/Project_Synthetic_promoters) led to the generation of libraries of 
single-responsive synthetic promoters with evenly spaced TFBSs. We further modified this approach to enable 
the assembly of synthetic promoters containing multimerised TFBSs cloned upstream of the mCMV promoter 
and the firefly luciferase gene (Supplementary Figure 1A).
The use of overlapping annealing sequences devoid of any TFBSs is fundamental to the Assembly PCR method 
to ensure that the annealing sequences are transcriptionally silent and this was confirmed using the TRANSFAC 
database30. We then determined optimal conditions for Assembly PCR promoter construction by first exploring 
the influence of annealing sequence length on PCR product formation (sequences detailed in Supplementary 
Table 2). Hypoxic response element (HRE)-oligonucleotides with 10 bp, 15 bp and 20 bp annealing sequences 
were assembled and amplified using Assembly PCR and analysis of the resulting PCR products by gel electropho-
resis confirmed the assembly and amplification of PCR products containing 15 bp and 20 bp annealing sequence. 
In contrast, the PCR products generated using the 10 bp annealing sequences were very small and indistinguish-
able from the amplification ‘stop’ primers (Supplementary Figure 1B and C) indicating inefficient PCR assembly, 
therefore, annealing sequences of 15 bp or 20 bp were used in subsequent reactions.
The ‘stop’ oligonucleotides serve three important functions in the Assembly PCR reaction; firstly, they 
truncate the PCR product to prevent infinite assembly, secondly, the incorporated 5′- and 3′-‘stop’ oligonu-
cleotides in the assembled PCR product serve as primer binding sites during the subsequent amplification 
reaction and thirdly, they contain restriction enzyme sites for further cloning. Therefore, the efficient incor-
poration of the ‘stop’ oligonucleotides in the PCR product during the initial ×10 cycle assembly reaction 
improves the efficiency of the amplification reaction, restriction digestion and ligation reactions. We com-
pared the use of ‘stop’ oligonucleotides over the concentration range of 16 nM to 260 nM, with equimolar 
forward and reverse-HRE oligonucleotides containing a 20 bp annealing sequence. As expected, increasing 
the ‘stop’ oligonucleotide concentration in the initial assembly reaction led to a reduction in the size of the 
assembled and amplified PCR products (Supplementary Figure 1D and E, respectively), indicating the effi-
cient truncation of the assembled PCR products with higher concentrations of ‘stop’ oligonucleotides. In 
order to generate compact promoters, we selected a ‘stop’ oligonucleotide concentration of 210 nM for use in 
subsequent assembly reactions.
Figure 2. Structure and function of 4bp composite synthetic promoters. Compact randomly assembled 
4bp synthetic promoter sequences are schematically represented in (A) (TFBS: AP-1 (red), NF-κ B (green), 
HRE (blue) the arrow direction indicates the orientation of TFBS and the black arrow represents the mCMV 
promoter). Basal promoter activity was assessed in transfected non-stimulated 293T cells and is illustrated in 
(B), comparison of basal expression of all promoters with the mCMV group was performed by 1 way ANOVA 
which showed significant differences. A post-hoc Tukey test was then performed to determine significant 
differences from the mCMV promoter and where p < 0.05 this is indicated by ★. (C) shows the luciferase 
activity upon stimulation of cells and these changes are expressed as fold changes from basal activity in (D). 
The responsiveness of each promoter in C to stimulation was also analysed by 1 way ANOVA (within each 
promoter). A post-hoc Šidak test was then performed to determine the level of significance of mean values 
above the activity of the unstimulated promoter. Where the difference from unstimulated promoter activity was 
not significant (p > 0.05) this is indicated by ns. When the activity with combined stimulation (grey bars) was 
significantly (p < 0.05) lower than the highest activation caused by an individual stimuli this is indicated by ★.
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Optimal spatial arrangement of  TFBSs relative to each other and to the TATA box for low basal 
promoter activity and maximal induction. Next, we investigated the effect of spatial preferences of 
proximal AP-1 and NF-κ B motifs relative to the TATA box within the synthetic promoters. PCR assembled pro-
moters containing 8xAP-1 or 6xNF-κ B motifs were cloned into the mCMV-Xbp vector which permitted sys-
tematic expansions over the range of 55 bp and 74 bp between the proximal TFBS and the TATA box (Fig. 3A). 
Interestingly, both AP-1 and NF-κ B-responsive promoters with the proximal TFBS located closest to the TATA 
box (55bp space) had the highest basal and highest induced luciferase gene expression levels and as the prox-
imal TFBS was positioned further from the TATA box, the basal and induced gene expression levels declined 
(Fig. 3B,D, respectively). Due to the higher basal expression with 55 bp spacing from the TATA box, the fold 
induction was lower at this distance with both AP-1 and NF-κ B TFBSs (Fig. 3C and E respectively). The 66bp 
distance from the TATA box gave lower basal expression than the 55 bp space when tested with NF-κ B and AP-1 
TFBSs and retained high induced luciferase expression, and was therefore utilised in all subsequent synthetic 
promoters.
We also explored the optimal spacing between neighbouring TFBSs on gene expression. Promoters 
were assembled containing either NF-κ B or AP-1 binding sites, separated by 15 bp to 60 bp space (Fig. 4A). 
Recombinant plasmids containing these responsive promoters were transiently transfected into 293T cells and 
were either unstimulated or stimulated with PMA or TNFα to activate AP-1 or NF-κ B, respectively (Fig. 4B–E). 
In both promoter libraries, the promoters with the shortest space (15 bp) between TFBS displayed the highest 
basal and induced luciferase gene expression compared to promoters with TFBSs separated by a greater distance. 
In these initial experiments, the number of TFBSs was not standardised, which could potentially influence the 
Figure 3. Optimisation of spacing between the TATA box and the proximal TFBS. The spacing between 
the TATA (T) box in the minimal CMV (mCMV) promoter and the proximal TFBS was altered as represented 
in (A) to examine the influence on regulated gene expression. The effect of increased spacing between the 
proximal AP-1 site and the TATA box was assessed in transfected 293T cells that are unstimulated (white bars) 
and stimulated with PMA (red bars) in B and as fold induction in (C). Similar studies on spacing between the 
proximal NF-κ B site and the TATA box in transfected 293T cells stimulated with TNFα (green bars) are shown 
in (D,E). Data in (B,D) was analysed by 2 way ANOVA to take into account the effect of the change in sequence 
length and the effect of stimulation upon the promoters. This analysis revealed that both factors had significant 
effects on promoter activity. A post-hoc Šidak test was then performed to compare the stimulated and non-
stimulated activity of each promoter and significant differences of p < 0.05 are indicated by ★.
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outcome of the experiment. We therefore compared the activity of synthetic promoters comprising the same num-
ber of TFBSs (8xNF-κ B motifs) within each spacer group. Transcriptional activity with the 8xNF-κ B-synthetic 
promoters also complied with the observed trend of higher basal activity and higher induced expression when 
TFBS were closer together compared to further apart (Fig. 4F and G). As 20 bp spacing between TFBSs was the 
shortest distance that allowed low basal activity and high induced luciferase expression, we applied this spacing 
to subsequent promoters.
Function of optimally spaced TFBS clusters and the effect of multi-stimulation. Endogenous 
promoters often contain repeats or clusters of the same TFBSs in close arrangements and this feature is thought to 
promote recruitment of the cognate TF and thus increase the transcription activity of the promoter. We therefore 
examined the influence of the number of NF-κ B binding sites on luciferase gene expression, following TNFα 
stimulation. The data in Fig. 5A clearly shows that with increasing number of TFBSs, there is a significant increase 
in TNFα -induction and as the number of NF-κ B motifs increases beyond 6, the induction levels remained rela-
tively unchanged. Similar cluster promoters were generated with HRE (6xHRE) and AP-1 (8xAP-1) motifs and 
interestingly, the activity of these mono-responsive cluster promoters was significantly lower upon multiple stim-
ulation compared to their optimal activation with a single stimulus (Supplementary Figure 2), thus supporting 
the activation profile of the mono-responsive promoters shown in Fig. 1.
Composite cluster promoters with optimally sized clusters. We then generated composite promot-
ers with clusters of 6xHRE, 6xNF-κ B and 8xAP-1. In these promoters, the proximal TFBS cluster was predeter-
mined by the choice of vector for the random cloning with the other two TFBS cluster types. Promoters were 
sequenced and shown to contain a single repeat of each cluster, with the central cluster orientated in the reverse 
direction and a total promoter length of 665 bp. Within these promoters, optimal spacing was retained between 
TFBS but a 46 bp space was introduced between clusters and these promoters displayed basal expression com-
parable to the parent vector in transfected 293T cells (Fig. 5B). Following cell stimulation, it was apparent that 
Figure 4. Optimisation of the spacing between TFBS in assembled promoters. Promoters were generated 
with increasing spacing between TFBS as represented in (A). Resulting promoters harbouring AP-1 sites were 
examined in transfected 293T cells that were unstimulated (black bars), stimulated with PMA (red bars) in 
(B) and with fold change illustrated in (C). The same spacing arrangements were assessed with NF-κ B sites in 
transfected cells stimulated with TNFα (green bars) (D) with fold changes shown in (E). Promoters with the 
same spacing and containing the same number of NF-κ B sites (8 in total) were also assessed in TNFα stimulated 
293T cells to eliminate any influence of binding site number on luciferase activity results (F) and fold induction 
shown (G). Data in F was analysed by 2 way ANOVA to take into account the effect of the change in spacing 
and the effect of stimulation upon the promoters. This analysis revealed that both factors had significant effects 
on promoter activity. A post-hoc Šidak test was then performed to compare the stimulated and unstimulated 
activity of each promoter and significant differences of p < 0.05 are indicated by ★.
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cluster promoters were predominantly activated through the proximal TFBS cluster and displayed less activation 
via other distal clusters (Fig. 5B). Importantly, combined stimulation did not result in additive induction of these 
promoters and indeed, several promoters displayed significantly lower induction with combined stimulation 
(Fig. 5B). These experiments show that the use of pre-constructed clusters did not generate optimally function-
ing multi-responsive promoters. These experiments also demonstrate that TNFα and hypoxia were specific for 
NF-κ B and HRE induction respectively, whereas PMA gave efficient activation of AP-1 and to a lesser extent 
NF-κ B. This activation of NF-κ B by PMA is in agreement with published literature on PMA31,32
Randomly generated composite synthetic promoters with the optimal spatial arrangement 
of TFBSs exhibit low basal activity, multi responsiveness and additive induction. We then con-
structed composite synthetic promoters with optimal 20 bp spacing between randomly arranged NF-κ B, AP-1 and 
HIF-1α motifs and a 66 bp space between the proximal TFBS and the TATA box. The overall incorporation rate of 
the three TFBSs in the 17 promoters sequenced was 35% HRE, 33% AP-1 and 32% NF-κ B, which suggests there 
was no bias in TFBS inclusion. The median number of TFBSs included in the promoters was 10.6 (range 2–26) 
which is an approximate length of 384 bp and promoters were generally error free with only 2 TFBSs and 2 spacing 
distances altered (Fig. 6A; Supplementary Material Appendix). Basal expression from all 20bp-composite synthetic 
promoters was low with an average of 12.1 RLU, which was only significantly higher than the mCMV alone (9.5 
RLU) in five promoters (Fig. 6B). Upon stimulation with hypoxia, TNFα or PMA, the promoters displayed appro-
priate induction based upon their sequence composition (Fig. 6C,D) and only 3 promoters (5, 15 and 18) displayed 
significantly lower induction with combined stimulation. Sequence analysis of the promoters supported the acti-
vation profiles of the promoters, for example the partial or non-responsiveness of promoters - 5, 14 and 18 may 
have been due to the presence of a single AP-1 site thus resulting in low PMA induction, whereas promoter 5 was 
Figure 5. Optimised TFBS number and responsiveness of cluster promoters. The influence of increasing the 
number of NF-κ B sites on promoter responsiveness to TNFα was assessed in transfected 293T cells as illustrated 
in A (white bars unstimulated, green bars TNFα stimulated). Cluster composite promoters were generated with 
each type of cluster (NF-κ B, AP-1 and HRE) in the proximal position. Basal activity and stimulated activity of 
these promoters is shown in (B). Data in (A) was analysed by 2 way ANOVA to take into account the effect of 
the change in number of NFkB clusters and the effect of stimulation upon the promoters. This analysis revealed 
that both factors had significant effects on promoter activity. A post-hoc Šidak test was then performed to 
compare the stimulated and non-stimulated activity of each promoter and significant differences of p < 0.05 
are indicated by ★. The responsiveness of each individual cluster promoter in (B) to stimulation was analysed 
by 1 way ANOVA. A post-hoc Šidak test was then performed to determine the level of significance of mean 
values above the unstimulated promoter activity. Where the difference from baseline promoter activity was 
significantly (p < 0.05) different this is indicated by ★. The post-hoc Šidak test also revealed when combined 
stimulation resulted in a significantly (p < 0.05) lower promoter activation than achieved with the optimal 
individual stimulation and is illustrated by red arrows.
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devoid of NF-κ B sites and was non-responsive to TNFα . Importantly, when all three stimuli were combined, the 
majority of the composite promoters (1, 4, 6, 9, 14, 16, 17, 19 and 20) displayed additive or synergistic induction.
Characterisation of dose- and time-dependent induction of luciferase gene expression following 
genomic integration of composite synthetic promoters. Using a lentiviral vector, we examined the 
responsiveness of promoters 9 and 14 following genomic integration in 293T cells. The promoter sequences and 
luciferase gene were cloned into a self-inactivating lentiviral vector containing the scaffold attachment region 
HS4 which insulates the expression cassette from external influences. The promoters retained the same activation 
profile following genomic integration but with a dramatically increased fold induction (Fig. 7A,B). The activity 
of promoter 9 was further explored in kinetic studies which revealed interesting differences between PMA and 
TNFα stimulation; promoter activation with PMA was observed as ‘all-or-nothing’ with significant and maximal 
activation with 1 ng/ml PMA (1390.8 fold) (Fig. 7C). In contrast, dose-dependent responsiveness was observed 
with TNFα induction from 100 pg/ml, with a peak induction observed between 50–100 ng/ml TNFα (146.6 fold) 
(Fig. 7C). Despite these differences, the kinetics of activation with 10 ng/ml of TNFα or PMA were similar, with 
promoter 9 activated after 8 hours of stimulation and reached peak induction between 24 and 48 hours (Fig. 7D). 
Importantly, the promoter displayed robust synergistic activation at almost all time-points with combined TNFα 
and PMA stimulation (Fig. 7D). Lentivirus transduced cells were maintained in culture for 40 days and retained 
stable levels of promoter function over this time frame (Supplementary Figure 3).
Composite synthetic promoters display disease-specific induction of luciferase gene expression 
in vivo. The in vivo disease-activation profile of promoter 9 delivered with a lentiviral vector was assessed in 
Figure 6. Organisation and function of composite promoters with randomly arranged TFBS. Generated 
promoters were sequenced and the arrangement of TFBS is schematically illustrated in (A) (TFBS: AP-1 (red), 
NF-κ B (green), HRE (blue) the arrow direction indicates the orientation of TFBS and the black arrow represents 
the mCMV promoter; X indicates TFBS error and ^ indicates site of spacing error). The basal activity of the 
promoters in unstimulated transfected 293T cells is shown in (B). Promoters were induced by stimulation of 
transfected cells with hypoxia (0.1%), TNFα , PMA and the three combined. Levels of luciferase activity are 
shown in (C) and fold changes in expression illustrated in D. Comparisons of basal expression of all promoters 
with the mCMV group in (B) was performed by 1 way ANOVA which showed significant differences. A post-
hoc Dunnett test was then performed to determine significant differences from the basal activity of the mCMV 
promoter and where p < 0.05 this is indicated by ★. The responsiveness of each individual promoter in (C) to 
stimulation was also analysed by 1 way ANOVA. A post-hoc Šidak test was then performed to determine the 
level of significance of mean values above the unstimulated promoter. Where the difference from unstimulated 
promoter activity was not significant (p > 0.05) this is indicated by ns. When the activity with combined 
stimulation (grey bars was significantly (p < 0.05) lower than the highest activation of the same promoter by an 
individual stimuli this is indicated by ★. 
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Figure 7. Promoter activity following lentiviral delivery in vitro and in vivo. 293T cells lentivirally 
transduced to habour promoters 9 and 14 were responsive to stimulation (A – Green/TNFα ; Red/PMA and 
Black their combination) with fold induction shown in (B). Transduced 293T cells with promoter 9 were 
used to study dose responsiveness of the promoter to increasing concentrations of TNFα (Green line) and 
(Red line) PMA (C). The kinetics of activation of promoter 9 were explored at time points up to 24 hours after 
promoter stimulation with TNFα , PMA and the combination of the two (black line) (D). Activity of promoter 
9 was then compared to the mCMV and constitutive SFFV promoter in a mouse paw inflammation model. 
www.nature.com/scientificreports/
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a carrageenan-induced paw inflammation model. Equal titres of lentiviruses encoding the luciferase gene driven 
by composite promoter 9, the constitutive promoter SFFV (positive control), or the mCMV (negative control) 
were injected intraplantarly into both hind paws of mice (n = 3) seven days before carrageenan administration to 
allow for genomic integration. Paw inflammation was induced by an intraplantar injection of 1% λ -carrageenan 
suspension into the left hind paw whilst an equal volume of sterile saline was injected into the control right 
hind paw. Luciferase gene expression was measured using real-time bioluminescence imaging (Supplementary 
Figure 4) before inflammation (0 hours) and at 3, 24 and 72 hours post-carrageenan injection (Fig. 7E–J) and 
paw thickness was measured up to 96 hours (Fig. 7E–J). As anticipated, at 0 hours (before inflammation) basal 
luciferase expression from composite promoter 9 was low and not significantly different from expression levels 
from the negative control promoter LV-mCMV (Supplementary Figure 5). Following carrageenan injection in 
the left hind paw, promoter 9 induced robust inflammation-specific luciferase expression which was significantly 
higher than in the control saline paw when assessed as area under the curve (Fig. 7I,J) The induction of promoter 
9 peaked after 3 hours at a level comparable with the SFFV promoter, whilst-paw thickness increased to a peak 
after 24–48 hours post-carrageenan injection (Fig. 7F,H,J). By 72 hours, inflammation was generally lower than 
at the previous time points but had not returned to baseline and the luciferase expression from the composite 
promoter had also declined. A contributory factor in the decline of luciferase activity was that increased paw 
thickness which could reduce photon emission from the luciferase enzyme, as observed in the SFFV promoter 
group (Supplementary Figure 6).
Discussion
Regulated synthetic promoters have potential applications in gene therapy of diseases where changes in gene 
expression can be attributed to defined TF activation. In order for these promoters to function optimally they 
will need to be responsive to all phases of disease activity and remain active whilst evidence of disease pathology 
persists. Previously described promoters containing a single TFBS type are mono-responsive19–21 so are unlikely 
to display an activation profile that mirrors disease course. Furthermore, observations in our study show that the 
activity of such mono-responsive promoters is compromised when multiple TFs are activated during combined 
stimulation. Importantly, this also included mono-responsive promoters constructed with the optimal spatial 
arrangement defined in this study. These observations may also provide an important caveat to the more general 
use of responsive promoters in the monitoring of TF activity. Ideally, disease-responsive promoters should be 
responsive to any TF involved in the disease pathology and should be maximally induced by each individual 
TF or all TFs, where the latter results in additive gene expression. By integrating molecular biology and compu-
tational bioinformatic studies of TFs, it should be feasible to delineate and exploit all transcriptional pathways 
activated in a particular condition for gene therapy application.
Core promoter motifs such as TATA boxes are integral to eukaryotic transcription as they serve as plat-
forms for the assembly of the transcriptional preinitiation complex (PIC), comprised of RNA pol II and its basal 
TFs. The formation of this PIC is sufficient for a basal level of transcription, however, regulated transcription 
is dependent on the recruitment of gene-, stimuli- or tissue-specific TFs to their cognate binding sites in the 
promoter regions of target genes33. In line with our observations, many studies have also demonstrated that 
expanding the distance between upstream elements i.e. TFBSs and the TATA box can reduce transcriptional acti-
vation34–41. Taken together, these publications suggest that the transcription initiation process requires specific 
alignments between TFBSs and the proteins assembled on the TATA box and it is likely that positioning the prox-
imal TFBS closer to the TATA box facilitates their interactions, which favour high gene expression. In designing 
regulated promoters our 66 bp spacing from the TATA box proved optimal for maintaining low basal activity but 
retention of high inducibility.
Surprisingly little exploration of the influence of TFBS spatial arrangements on promoter activity have been 
performed. Most previous work has been on spacing between TFBS in constitutive synthetic promoters with 
evidence that closely aligned TFBS can result in steric hindrance. Observations in yeast with synthetic GAL4 
promoters have shown reduced expression when 2 adjacent sites were separated by 1 bp and a weaker effect 
was observed for Gcn4 sites positioned 5 bp apart40. Increasing the spacing between TFBS has also been shown 
to influence the activity of synthetic constitutive promoters, activity of a Gal4-VP16 promoter declined when 
spacing between two binding sites was increased from 0 to 48 bp42. Similarly, our studies revealed that spacing 
between TFBS also influenced promoter induction. Firstly, basal activity was elevated with closer (4 bp and 15 bp) 
spacing between TFBS but was lower when the spacing was 20 bp or more, regardless of the TFBS arrangement 
monitored. These observations suggest that the architecture of the DNA sequence with closely aligned TFBS has 
Expression of luciferase was monitored in whole mice by non-invasive bioluminescent imaging a week after 
delivery of the virus (time 0) and at intervals after induction of inflammation in the left hind paw by injection 
of λ –carrageenan. Bioluminescence imaging results are shown in Supplementary Figure 4 and both fold 
change in bioluminescence from the time 0 baseline (red line) and paw thickness (blue line) were plotted for 
control (E,G,I) and inflamed paws (F,H,J). Multiple comparisons of mean data in (A,C,D) was analysed by 1 
way ANOVA which showed significant differences. A post-hoc Dunnett test was then performed to determine 
significant increases above unstimulated promoter activity with p values less than 0.05 indicated by ★. Data 
presented in E to I was analysed for each mouse using Graphpad Prism. Area under the curve was calculated 
for paw thickness and bioluminescence and then a 2-ANOVA was performed which confirmed there were 
significant effects of time and treatment. A post-hoc Bonferroni test confirmed a significant (p < 0.05) decline 
in the bioluminescence from the SFFV promoter in the inflamed paw compared to the saline control and that 
activity of promoter 9 was significantly (p < 0.05) increased in the inflamed paw compared to the saline control.
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an innate ability to drive gene expression in the absence of cell stimulation. In the unstimulated state levels of 
activated TFs will be low and an observation made in E.Coli that may be relevant, is that clusters of TFBS (two 
or more sites) are able to enhance TF binding rates at low concentrations43. With closer spacing (15 bp) in PCR 
assembled promoters there were also increased levels of induced expression and this also declined as spacing was 
increased (up to 45 bp). Because we were interested in designing promoters with a low basal expression and high 
induction we opted for spacing of 20 bp between TFBS in subsequent composite promoters. This spacing equates 
to a distance of 26 to 30 bp between the centre of adjacent TFBS which is between 2 and 3 turns of the DNA helix 
(20.9 and 31.35 bp respectively) and will position adjacent TFBS on different planar surfaces of the DNA helix.
Many highly active, endogenous human promoters possess clusters of the same type of TFBS44 and studies on 
the theory of facilitated diffusion of TFs indicate that ‘homotypic’ clusters facilitate the recruitment of TFs during 
their one-dimensional random search on the DNA for cognate TFBSs45–49. We therefore anticipated that pro-
moters generated with clusters of the same TFBS would exhibit high induction. We observed that increasing the 
number of clustered TFBSs resulted in a gene expression plateau, suggesting that synthetic promoters can become 
saturated with TFs, as also demonstrated in hypoxia-responsive synthetic promoters21. However, the function 
of the composite clustered promoters was not optimal because they were predominantly activated through the 
proximal TFBS cluster and thus displayed lower induction when other distal TFBS clusters in the promoter were 
activated. Furthermore, following combined stimulation, the composite clustered promoters failed to display 
additive induction, therefore additional studies are required to determine the optimal arrangements of clustered 
TFBSs within synthetic promoters to achieve the desired expression profile.
The composite promoters created using Assembly PCR generally displayed low basal activity and were appro-
priately responsive to individual stimuli. In many cases, they displayed additive induction or synergistic activa-
tion following combined stimulation (Fig. 6). Although the number of promoters characterised in vitro is small, it 
is apparent that the best functioning promoters had an even proportion of HRE, AP-1 and NF-κ B motifs distrib-
uted randomly throughout the promoter rather than containing clusters of homotypic TFBS. With high through-
put analysis it should be possible to establish mathematical models for promoter behaviour which will permit the 
design of promoters with desired functionality. In addition, such modelling may permit better interpretation of 
endogenous promoter activation and better understanding of mechanisms involved in gene regulation.
More detailed analysis of synthetic promoter function was undertaken following integration into the genome 
by lentiviral transduction. The dose responsiveness of composite promoter 9 to TNFα stimulation was similar to 
observations made with homotypic NF-κ B promoters50. Interestingly, the magnitude of induction was dramati-
cally improved when integrated into the genome with a lentiviral vector. There are several potential causal factors: 
a) the CpG motifs in the plasmid DNA can activate cells and thus promote higher basal activity and so reduce 
the magnitude of promoter activation51 b) the innate preference of lentiviruses to integrate into transcriptionally 
active sites52 and c) the use of HS4 insulation elements which bound the integrated promoter, has previously been 
shown to increase the activity of lentivirus integrated promoters due to better transcriptional termination53,54. 
In addition, the HS4 elements may also contribute to maintaining promoter function, as the HS4 insulators and 
bounded transgenes become acetylated and this modification is thought to be important in preventing methyl-
ation over the promoter55. Lentivirally integrated promoter 9 was shown to be highly sensitive, rapidly activated 
and exhibited dose- and time-dependent responses to stimulation.
In vivo studies with local delivery of promoter 9 in mouse paws confirmed disease-specific induction of lucif-
erase gene expression following carrageenan-induced paw inflammation, as determined by real-time biolumi-
nescence imaging. These observations confirm that locally activated TFs at the disease site are able to activate the 
promoter in a disease specific manner. Activity of the promoter peaked at 3 hours and was lower when inflamma-
tion peaked at 24 to 48 hours, however, observations with the SFFV promoter group suggest that the increased 
tissue thickness in the inflamed paws negatively impacts on the luciferase light emission which would lead to an 
underestimation of the promoter activity in inflamed tissue which we have previously suggested23. Further studies 
are therefore required to determine how closely promoter activation mirrors the profile of paw inflammation.
The use of assembly PCR to generate composite synthetic promoters has several advantages as it permits ran-
domness in TFBS arrangement and primers can be designed to include diversity within the consensus sequence of 
TFBS, in addition the length of assembled promoters can be broadly controlled through the concentration of stop 
oligonucleotides used in assembly reactions. Several generated promoters with optimised spatial arrangement 
had the functional characteristics we desired – compact, low basal activity, multi-responsiveness and additive 
induction. The assembly process and spacing arrangements described are also applicable to synthetic biology 
where promoters are used as logic gates. We have generated promoters with OR logic (promoter 4) which was 
similarly responsive to all three stimuli whilst other promoters were closer to AND logic (promoter 1). Clearly 
the spacing and screening was designed to select for promoter activation but could be optimised for the selection 
of other logic gates.
Methods
Cell culture, transient transfection and cell stimulation. Human embryonic kidney 293T (HEK293T) 
cells were grown in Dulbecco’s Modified Eagle’s Medium (DMEM) (Lonza Group Ltd., Switzerland) supple-
mented with 10% heat-inactivated foetal bovine serum (FBS; Gibco, Life Technologies Corp, California, USA), 
4.5g/L glucose (Sigma Aldrich, Corp, St Louis, MO, USA), 100 IU/ml penicillin (Sigma Aldrich), 100 μg/ml strep-
tomycin (Sigma Aldrich) and 2 mM L-glutamine (Sigma Aldrich) and were maintained at 37 °C in a humidified 
10% CO2 incubator. Twenty-four hours prior to transfection, 293T cells were seeded at a density of 2 × 104 cells 
in 96-well plates containing DMEM supplemented with 10% FBS and antibiotics. After 24 hours, the cells were 
co-transfected in triplicate with a total concentration of 200 ng/well DNA (180 ng firefly luciferase expressing 
recombinant plasmid DNA and 20 ng renilla luciferase expressing plasmid (pRL-CMV; Promega Corp., Madison, 
WI)) using FuGENE 6 Transfection Reagent (Promega Corp). Following 24 hours post-transfection, the cell 
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medium was replaced with DMEM containing 0.5% FBS alone for the unstimulated control cells and incubated 
in normal conditions for 18 hours. For the activation of HIF-1α , DMEM containing 0.5% FBS alone was added to 
the cells and the plate was incubated in hypoxic conditions at 0.1% O2, 10% CO2 and 89.9% N2 in a CO2 incubator 
(New Brunswick, Hamburg, Germany) for 18 hours. For the activation of inflammation-responsive TFs and/or all 
TFs, the cells in DMEM containing 0.5% FBS were stimulated with 10 ng/ml human TNFα (Activation of NF-kB 
-Peprotech, NJ, USA) or 10 ng/ml PMA (Activation of AP-1 - Sigma Aldrich) or a combination of 10 ng/ml TNFα 
and 10 ng/ml PMA in 0.1% hypoxia for 18 hours.
Assembly PCR method. A detailed description of the Assembly PCR method, including the subsequent 
construction of synthetic promoters in plasmids, lentiviral vectors and the generation of lentiviruses is described 
in the supplementary material.
Lentiviral stable cell lines and cell stimulation. Human kidney 293T cells (5 × 104) were seeded in 
complete DMEM medium in a 6-well plate, 24 hours before lentivirus transduction. Lentivirus particles (approx-
imately 3.5 × 105 IFU) were added to the cells supplemented with 6 μ g/ml polybrene and incubated for 72 hours, 
after which the transduced cells were trypsinised and cultured in complete DMEM using standard protocols. For 
the dose-response experiments, the transduced 293T cells (2 × 104 in 96-well plates) either remained unstimu-
lated or were stimulated with 0.001, 0.01, 0.1, 1, 10, 50 or 100 ng/ml of PMA or TNFα for 18 hours. For the time 
course experiments, transduced cells (2 ×104 in 96-well plates) were either unstimulated or stimulated with 10 ng/
ml PMA, 10 ng/ml TNFα or their combination for 2, 8, 12 and 24 hours. Firefly luciferase expression was normal-
ised to the total protein content in the same sample and also to the titre of the respective lentivirus and the data 
was expressed as RLU/mg protein/lenti IFU.
Luciferase assay and BCA assay. The luciferase activity in transiently transfected and transduced cell 
lysates was measured 18 hours post-stimulation by removing cell medium and lysing the cells in 50 μl of 1× 
Passive Lysis Buffer (Promega) or 50 μ l of 1× Glo Lysis Buffer (Promega), respectively, at room-temperature 
for 15 minutes with orbital shaking. The intracellular firefly and renilla luciferase expression in the same sam-
ples were quantified using the Luciferase Assay System (Promega) and the Renilla Luciferase Assay System 
(Promega), respectively, following the manufacturer’s instructions with minor modifications. The luciferase 
data was expressed as relative light units (RLU), as determined by the MLX Microtiter Plate Luminometer and 
Revelation software (Dynex Technologies Inc, Chantilly, VA, USA). The total protein concentration in transduced 
cell lysates was quantified using the Pierce BCA Protein Assay Kit (Thermo Scientific, Rockford, IL, USA) as per 
the manufacturer’s protocol and absorbance measurements at 562 nm were performed using a Tecan Genios 
Microplate Reader (Tecan Group Ltd, Männedorf, Switzerland) and Magellan 4 software. Firefly luciferase values 
from transduced cells were normalised to the total protein concentration in the same samples and expressed as 
relative light units per milligram of protein (RLU/mg).
Intraplantar delivery of lentiviruses to mouse paws. All experiments with adult male CD1 mice (6–8 
weeks old) were approved and performed under Home Office regulations (Scientific Procedures Act 1986) and 
in vivo lentivirus experiments were performed under strict biological containment. Mice were anaesthetised 
with AErrane (Isofluorane; Baxter Healthcare Ltd, Thetford, Norfolk) using Boyle’s apparatus (British Oxygen 
Company BOC, London, UK) and 25 μ l of the lentiviruses, LV.9.Luc+, LV.mCMV.Luc+ or LV.SFFV.Luc+, contain-
ing 260,000 lentivirus IFU in DMEM, were injected intraplantarly into both hind paws of the mouse and allowed 
to integrate into the cell genome for 7 days.
Carrageenan-induced paw inflammation model. Seven days post-lentivirus injection, inflamma-
tion was induced in the left hind paws of mice by intraplantar injection with 50 μ l of 1% λ -carrageenan (Sigma 
Aldrich) in saline (w/v) and the right hind paws received an equivalent volume of sterile saline, as control. 
Paw thickness, was measured at 0, 3, 24, 48 and 72 hours post-carrageenan injection using POCO 2T calipers 
(Kroeplin Längenmesstechnik, Schlüchtern, Germany).
In vivo bioluminescence imaging. Whole body luciferase activity in mice was non-invasively monitored 
at 0, 3, 24 and 72 hours post-carrageenan injection using real-time bioluminescence imaging. Mice received 
an intraperitoneal injection with 200 μ l of luciferin K+ Salt (30 mg/ml; Promega Corp) and were anaesthetised 
with isofluorane 15 minutes before imaging. Anaesthetised mice were photographed (0.2-second exposure) and 
imaged for light emission (5 minutes on medium sensitivity) with the IVIS 1000 series (Caliper Life Sciences 
Corp, Hopkinton, MA, USA). Bioluminescence images were overlaid on gray-scale photographs which were 
obtained with a 12-cm field of view, a binning of 8 and a 1/f stop and open filter. The regions of interest (ROI) 
were defined manually over both hind paws and the background photon flux was defined in control regions of the 
same size, to obtain quantitative photon data. Light emission was quantified as photons per steradian per square 
centimetre (photons/second/steradian/cm2/) using Living Image Software (Caliper Life Sciences Corp).
Statistical Analysis. Statistical analysis was performed using SPSS software (IBM SPSS Statistics 23), 
Graphpad Prism 4 version 4.03 (GraphPad Software, Inc., La Jolla, CA, USA) and Microsoft Excel (Microsoft 
Corp, Redmond, WA, USA). The statistical tests performed on each data set are described in the relevant figure 
legends.
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